Impact on Quality of Life in Patients Undergoing Total Gastrectomy or Proximal Gastrectomy for Adenocarcinoma of Esophagogastric Junction (GCQOL01)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01697917
Verified September 2012 by Yanong Wang, Fudan University. Recruitment status was: Recruiting
The purpose of this study is to find out more about differences of the quality of life in patients undergoing total gastrectomy or proximal gastrectomy for adenocarcinoma of esophagogastric junction. To find a better reconstruction for patients who received total gastrectomy.
Condition or disease
Adenocarcinoma of Esophagogastric Junction.
Other: Total Gastrectomy or Proximal Gastrectomy
Overall, the incidence of stomach cancer worldwide is declining with geographical variation. However, an increase in the incidence rate of adenocarcinoma of esophagogastric junction, called cardia or AEG has been observed in recent years. AEG may represent a specific histopathological and biologic entity. In the treatment AEG there is argument over whether proximal gastractomy(PG) or total gastractomy (TG) should be done. The quality of life (QOL) of the patients following TG or PG arouses people's attention. The purpose of this study was to evaluate differences of the quality of life in patients undergoing total gastrectomy or proximal gastrectomy for adenocarcinoma of esophagogastric junction.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years to 75 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
• Pathologically confirmed gastric malignant tumor at FUSCC (biopsy may be performed at other institutions but slides must be confirmed at FUSCC, as is routine care at our institution), and the patients be assessed can achieve R0 radical dissection through total gastrectomy or proximal gastrectomy by three specialists.
Patients 20-75 years old
Normal organ function, able to tolerate surgery, no clear contraindication for surgery
No evidence of metastases of adjacent organs
be able to provide follow-up over 2 years
No specific treatment for gastric cancer before surgery
In line with the Declaration of Helsinki and the requirements of the hospital ethics committee.
The subjects were able to understand and comply with the trial protocol, and signed informed consent.
• AEG SiewertⅠtype patients
Synchronous or metachronous (less than five years) and patients with other malignancies.
Cirrhosis and portal hypertension
Associated with blood diseases
Serious heart/ lung and kidney dysfunction or with metabolic diseases such as diabetes, hyperthyroidism.
Suffering from a serious neurological disease or psychological diseases affecting the life.